Organon & Co.

OGNSEC EDGAR

Pharmaceutical PreparationsCIK: 1821825

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$6.3B	$6.2B	$6.3B	$6.5B	$7.8B
Cost of Goods and Services Sold	$2.5B	$2.3B	$2.4B	$2.1B	$2.3B
Gross Profit	$3.7B	$3.9B	—	—	—
Research and Development Expense	—	—	—	—	$220.0M
Selling, General and Administrative Expense	$1.9B	$1.7B	$1.7B	$1.4B	$1.4B
Interest Expense	$527.0M	$422.0M	$258.0M	$0.00	$0.00
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$673.0M	$1.1B	$1.5B	$2.8B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$13.1B	$12.1B	$11.0B	$10.7B	$10.1B
Assets, Current	$4.3B	$4.5B	$3.9B	$3.8B	$3.6B
Cash and Cash Equivalents, at Carrying Value	$675.0M	$693.0M	$706.0M	$737.0M	$12.0M
Accounts Receivable, after Allowance for Credit Loss, Current	$1.4B	$1.7B	$1.5B	$1.4B	$1.0B
Inventory, Net	$1.3B	$1.3B	$1.0B	$915.0M	$913.0M
Liabilities	$12.6B	$12.1B	$11.8B	—	—
Liabilities, Current	$2.7B	$2.9B	$2.5B	$2.6B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$799.0M	$858.0M	—	—	—
Net Cash Provided by (Used in) Investing Activities	-$260.0M	-$420.0M	—	—	—
Net Cash Provided by (Used in) Financing Activities	-$569.0M	-$433.0M	—	—	—
Payments to Acquire Property, Plant, and Equipment	$251.0M	$196.0M	$192.0M	$255.0M	$92.0M
Payments of Dividends	$294.0M	$290.0M	$145.0M	$0.00	$0.00

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)